Abstract
Purpose
To study the effects of delaying pegfilgrastim administration following high-dose cytarabine (HiDAC) consolidation in AML patients on time to neutrophil count recovery, infectious complications, and survival.
Methods
Single-center retrospective chart review of 55 patients receiving pegfilgrastim as early administration (within 72 h) or delayed administration (after 72 h) of HiDAC.
Results
The difference in neutrophil recovery time was similar between the early and delayed groups (18 days versus 19 days, p < 0.28). Infections were seen in four patients in the early administration group following chemotherapy compared to none in the delayed group (p = 0.04). Febrile neutropenia rates were also decreased in the delayed administration group (23.1% versus 10.3%, p = 0.28) as well as a trend towards longer median survival (16 months versus 19 months, p = 0.69) and overall survival (21 months versus 31 months, p = 0.47).
Conclusion
A difference in time to neutrophil recovery was not observed between the early and delayed administration groups yet decreased infectious complications may support the delayed administration of pegfilgrastim in these patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data Availability
All data and materials comply with standards.
References
Dombret H, Gardin C (2016) An update of current treatments for adult acute myeloid leukemia. Blood 127(1):53–61. https://doi.org/10.1182/blood-2015-08-604520
Döhner H, Wei AH, Appelbaum FR et al (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140(12):1345–1377. https://doi.org/10.1182/blood.2022016867
Bloomfield CD, Lawrence D, Byrd JC et al (1998) Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58(18):4173–4179
Petros WP (1992) Pharmacokinetics and administration of colony-stimulating factors. Pharmacotherapy 12:32S-38S. https://doi.org/10.1002/j.1875-9114.1992.tb02680
Neulasta® OnPro® [package insert]. Thousand Oaks, CA: Amgen Inc; 2018
Zwick C, Hartmann F, Zeynalova S et al (2011) Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia. Ann Oncol 22(8):1872–1877. https://doi.org/10.1093/annonc/mdq674
Ottmann OG, Bug G, Krauter J (2007) Current status of growth factors in the treatment of acute myeloid and lymphoblastic leukemia. Semin Hematol 44(3):183–192. https://doi.org/10.1053/j.seminhematol.2007.04.007
Böhm A, Piribauer M, Wimazal F et al (2005) High dose intermittent ARA-C (HiDAC) for consolidation of patients with de novo AML: a single center experience. Leuk Res. 29(6):609–615. https://doi.org/10.1016/j.leukres.2004.10.009
Jaramillo S, Benner A, Krauter J et al (2017) Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia. Blood Cancer J 7(5):e564. https://doi.org/10.1038/bcj.2017.45
Kam G, Yiu R, Loh Y et al (2015) Impact of pegylated filgrastim in comparison to filgrastim for patients with acute myeloid leukaemia (AML) on high-dose cytarabine (HIDAC) consolidation chemotherapy. Support Care Cancer 23(3):643–649. https://doi.org/10.1007/s00520-014-2417-7
Sierra J, Szer J, Kassis J et al (2008) A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 8:195. https://doi.org/10.1186/1471-2407-8-195
van Der Auwera P, Platzer E, Xu ZX et al (2001) Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (ro 25–8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol. 66(4):245–251. https://doi.org/10.1002/ajh.1052
Author information
Authors and Affiliations
Contributions
All authors have made substantial contributions to the conception/design of the project, data analysis and interpretation, and manuscript draft and review.
Corresponding author
Ethics declarations
Ethics approval
This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Institutional Review Board at WVU Hospitals.
Consent to participate
Not applicable—research was retrospective in nature.
Consent for publication
All authors grant final approval of the manuscript draft for publication.
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Yingling, S.K., Francis, J., Seago, K. et al. Efficacy of delayed pegfilgrastim administration following consolidation therapy with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) patients. Support Care Cancer 32, 276 (2024). https://doi.org/10.1007/s00520-024-08480-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00520-024-08480-9